Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.55 |
| ▸ | HTR1A | P08908 | 6/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776632 | 0.89 | IDO1 (0.54) | SLC6A2SLC6A4SLC6A3HTR1AIDO1 | |
| SCHEMBL20328108 | 0.84 | IDO1 (0.54) | SLC6A2SLC6A4SLC6A3HTR1AIDO1 | |
| Hydrochloric Acid SCHEMBL29586373 | 0.83 | IDO1 (0.52) | SLC6A2SLC6A4SLC6A3HTR1AIDO1 | |
| SCHEMBL19284609 | 0.81 | HTR2C (0.53) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL30735659 | 0.81 | HTR2C (0.53) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL30735591 | 0.81 | HTR2C (0.56) | HTR6HTR2C | |
| SCHEMBL19297231 | 0.81 | HTR2C (0.56) | HTR6HTR2C | |
| Hydrochloric Acid SCHEMBL19284700 | 0.80 | HTR2C (0.54) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL2710242 | 0.80 | HTR2C (0.56) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL30368566 | 0.80 | HTR2C (0.56) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | SLC6A2 2418/4885SLC6A4 1958/4885SLC6A3 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.